KDR and idiopathic pulmonary fibrosis: Similarly, the broad tyrosine kinase inhibitor nintedanib (anti-VEGFR, -FGFR, -PDGFR), developed as an angiogenesis inhibitor, increases responses to docetaxel in non–small cell lung cancer patients (47) and has also shown some efficacy in the treatment of idiopathic pulmonary fibrosis (48).